Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced the start of the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab (anti-KIR) and nivolumab (anti-PD-1) in selected solid tumors.

Additional details are available at clinicaltrials.gov

Lirilumab is licensed to Bristol-Myers Squibb Company (NYSE: BMY) and this Phase I trial is being conducted by Bristol-Myers Squibb.

About the Phase I trial with lirilumab (anti-KIR checkpoint inhibitor; BMS-986015) in combination with nivolumab (anti-PD-1 checkpoint inhibitor BMS-936558) in solid tumors:

The purpose of this Phase I open label study is to evaluate the safety of the combination of lirilumab and nivolumab and to provide preliminary information on the clinical activity of the combination. The primary outcome is safety. Secondary outcomes include a preliminary evaluation of efficacy, as measured by tumor assessment. It is conducted in two parts: dose escalation and cohort expansion. In the cohort expansion, patients will be dosed for up to two years.